Abstract:Objectives: We aimed to study the effect of antibiotic-induced disruption of gut microbiome on host metabolomes and inflammatory responses after long-term use of antibiotics. Methods: A total of three groups of 3-week-old female C57BL/6 mice ( n = 44) were continuously treated with vancomycin (VAN), polymyxin B (PMB), or water, respectively, for up to 28 weeks. Fecal samples collected at different time points were analyzed by bacterial 16S rRNA gene sequencing and untargeted metabolomics by ultraperformance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry (UPLC Q-TOF MS). Serum cytokines (IFN-γ, IL-2, IL-10, IL-13, IL-17A, and TNF-α) were determined by multiplex immunoassay. Results: Treatment by VAN or PMB did not affect the average body weight of mice. However, a heavier caecum observed in VAN-treated mice. Compared with PMB-treated and control mice, VAN treatment induced more rapid dysbiosis of gut microbiota and dysmetabolism. Instead of Bacteroides , VAN-treated mice had a compositional shift to Proteobacteria and its species Escherichia coli and Verrucomicrobia and its species Akkermansia muciniphila . The shift was accompanied by decreased richness and diversity in microbiota. PMB-treated mice had an increased Firmicutes , and the diversity was shortly increased and further decreased to the baseline. Decreased levels of short-chain and long-chain fatty acids, bile acids, L-arginine, dopamine, L-tyrosine, and phosphatidylcholine (all p < 0.05) were observed in VAN-treated mice. In contrast, significantly increased levels of amino acids including L-aspartic acid, beta-alanine, 5-hydroxy-L-tryptophan, L-glutamic acid, and lysophosphatidylcholines (all p < 0.05) were found. These changes occurred after 3-week treatment and remained unchanged up to 28 weeks. For PMB-treated mice, metabolites involved in the metabolic pathway of vitamin B6 were decreased, whereas glycocholic acid and chenodeoxycholic acid were increased (all p < 0.05). After 8-week treatment, VAN-treated mice had significantly higher levels of serum IFN-γ, IL-13, and IL-17A, and PMB-treated mice had higher levels of IL-13 and IL-17 compared to control mice. At 28-week treatment, only IL-17A remained high in PMB-treated mice. Conclusion: This study showed that the antibiotic-induced alterations in gut microbiota contribute to host inflammatory responses through the change in metabolic status, which are likely related to the type, rather than timing of antibiotic used.

Antibiotics-induced Perturbations in Gut Microbial Diversity Influence Metabolic Phenotypes in a Murine Model of High-Fat Diet-Induced Obesity

High-fat-diet-induced gut microbiome changes in mice

Effect Of The Short-Term Use Of Fluoroquinolone And Beta-Lactam Antibiotics On Mouse Gut Microbiota

Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet

Antibiotics administration alleviates the high fat diet-induced obesity through altering the lipid metabolism in young mice

Gut microbiome alterations in high-fat-diet-fed mice are associated with antibiotic tolerance

Sex-specific Association Between the Gut Microbiome and High-Fat Diet-Induced Metabolic Disorders in Mice

Trans-fatty Acids Alter the Gut Microbiota in High-Fat-diet-induced Obese Rats

Alteration of gut microbiota affects expression of adiponectin and resistin through modifying DNA methylation in high-fat diet-induced obese mice

Changes in Gut Microbiota in Rats Fed a High Fat Diet Correlate with Obesity-Associated Metabolic Parameters

High-Fat Diet Induces Dysbiosis of Gastric Microbiota Prior to Gut Microbiota in Association with Metabolic Disorders in Mice

Antibiotics cause metabolic changes in mice primarily through microbiome modulation rather than behavioral changes

The effect of different combinations of antibiotic cocktails on mice and selection of animal models for further microbiota research

Gut microbiota affects obesity susceptibility in mice through gut metabolites

Modulation of gut microbiota by antibiotics improves insulin signalling in high-fat fed mice

Effects of Oral Florfenicol and Azithromycin on Gut Microbiota and Adipogenesis in Mice

Distinct Gut Microbiota and Arachidonic Acid Metabolism in Obesity-Prone and Obesity-Resistant Mice with a High-Fat Diet

Integrated Analysis of the Alterations in Gut Microbiota and Metabolites of Mice Induced After Long-Term Intervention With Different Antibiotics

Dysbiosis of Intestinal Microbiota in Early Life Aggravates High-Fat Diet Induced Dysmetabolism in Adult Mice

Antibiotic-Induced Dysbiosis of the Gut Microbiota Impairs Gene Expression in Gut-Liver Axis of Mice

The Role of Gut Microbiota in the Resistance to Obesity in Mice Fed a High Fat Diet